(redirected from Cholesteryl ester transfer protein)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to protein

References in periodicals archive ?
Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers.
Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency.
Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).
Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.
Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein.
SproutGarden-C inhibits activity of Cholesteryl Ester Transfer Protein (CETP) in vivo.
It will not be until the completion of combination trials using statin plus niacin analogs and statin plus cholesteryl ester transfer protein inhibitors vs statin alone by 2012-2014 that we will have a better idea as to how to treat 2 other independent CHD risk factors: low HDL cholesterol and increased lipoprotein or Lp(a).
Experience with torcetrapib, an inhibitor of the cholesteryl ester transfer protein (CETP), has raised the most profound questioning regarding the value of increasing HDL-C concentrations to decrease cardiovascular risk.
Cholesteryl ester transfer protein inhibition, highdensity lipoprotein metabolism and heart disease risk reduction.
anacetrapib (formerly known as MK-0859), its investigational selective cholesteryl ester transfer protein (CETP) inhibitor, significantly reduced LDL-cholesterol (LDL-C) and Apolipoprotein B (Apo B) and increased HDL-cholesterol (HDL-C) and Apolipoprotein A-1 (Apo A-1) both as monotherapy and in combination with atorvastatin 20 mg compared to placebo in patients with dyslipidemia.
The recent failure to prevent coronary disease with torcetrapib, a major inhibitor of the cholesteryl ester transfer protein (CETP) [2] system, indicated that this therapeutic approach is disputable.
Torcetrapib, a potent cholesteryl ester transfer protein inhibitor, markedly raised HDL-cholesterol levels, decreased LDL-cholesterol levels, and increased the particle size of both types of cholesterol in a pilot study, reported Margaret E.
ITI) the manufacturer and distributor of highly efficacious, natural medicines, sees the abrupt halt of the Pfizer clinical trials of torcetrapib as a harsh warning to pharmaceutical companies looking to develop synthetic drugs that increase HDL by suppressing cholesteryl ester transfer protein (CETP).
3, 2014 /PRNewswire/ -- Decision Resources Group finds that the novel proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and cholesteryl ester transfer protein (CETP) inhibitors will stimulate significant growth in the dyslipidemia market over the latter half of the 2013-2023 forecast period.